Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Fogelman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Psychiatric Clinics of North America|January 7, 2000
Clinician safetyJ R Brasić, D Fogelman
Journal of Clinical Microbiology|July 16, 1999
Salmonella enterica serotype Dublin infection: an emerging infectious disease for the northeastern United StatesP L McDonough, D Fogelman, S J Shin, et al.
Analytical Chemistry|June 7, 2011
Rate measurements by the pulsed-accelerated-flow methodC P Bowers, K D Fogelman, J C Nagy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2018
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancerM J Overman, L Adam, K Raghav, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancerM J Overman, L Adam, K Raghav, et al.
Investigational New Drugs|June 12, 2015
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancerS M Reddy, S Kopetz, J Morris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2016
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsM J Overman, V Morris, B Kee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2024
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyT André, K-K Shiu, T W Kim, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Psychiatric Clinics of North America|January 7, 2000
Clinician safetyJ R Brasić, D Fogelman
Journal of Clinical Microbiology|July 16, 1999
Salmonella enterica serotype Dublin infection: an emerging infectious disease for the northeastern United StatesP L McDonough, D Fogelman, S J Shin, et al.
Analytical Chemistry|June 7, 2011
Rate measurements by the pulsed-accelerated-flow methodC P Bowers, K D Fogelman, J C Nagy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2018
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancerM J Overman, L Adam, K Raghav, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancerM J Overman, L Adam, K Raghav, et al.
Investigational New Drugs|June 12, 2015
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancerS M Reddy, S Kopetz, J Morris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2016
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsM J Overman, V Morris, B Kee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2024
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyT André, K-K Shiu, T W Kim, et al.
Pageof 1